Cathy Eng Archives
Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial
Sep. 13, 2022—Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.
Aug. 17, 2022—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.
Jan. 25, 2022—New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.
Sep. 23, 2021—Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
Nov. 18, 2020—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
Jun. 24, 2020—People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.
Feb. 5, 2020—Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
Aug. 7, 2019—Younger patients say colorectal cancer is a disease that doesn’t follow age guidelines, so pay attention to early symptoms.
Jun. 13, 2019—Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).